These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36740773)

  • 1. Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e638-e639. PubMed ID: 36740773
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Treatment of Patients With Primary Aldosteronism.
    Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
    Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperaldosteronism].
    Scholl UI
    Internist (Berl); 2021 Mar; 62(3):245-251. PubMed ID: 33599784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
    Weiner ID
    Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?
    Pitt B; Williams GH
    Circulation; 2024 Feb; 149(6):414-416. PubMed ID: 38315762
    [No Abstract]   [Full Text] [Related]  

  • 16. Aldosterone and arterial hypertension.
    Tomaschitz A; Pilz S; Ritz E; Obermayer-Pietsch B; Pieber TR
    Nat Rev Endocrinol; 2010 Feb; 6(2):83-93. PubMed ID: 20027193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
    Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
    JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary aldosteronism and low-renin hypertension: a continuum?
    Funder JW
    Nephrol Dial Transplant; 2013 Jul; 28(7):1625-7. PubMed ID: 23535225
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
    Schumacher CD; Steele RE; Brunner HR
    J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.